GLASS-AMR manual
Feedback from countries

3rd High Level Technical Consultation and Meeting on Surveillance of Antimicrobial Resistance and Use for Concerted Actions

Sergey EREMIN, MD, PhD
Team Lead, Evidence and Emerging Resistance
Surveillance, Prevention and Control Department, AMR Division
WHO Headquarters, Geneva
Updated GLASS methods for AMR surveillance in humans

- Part of a package of documents and tools to inform GLASS 2.0 implementation
- Describes the objectives and methodology of GLASS-AMR
- Provides guidance for countries on the GLASS-AMR methods and metrics
- The intended readership includes national GLASS focal points, national public health professionals and national health authorities responsible for AMR surveillance in humans, and those contributing to national surveillance data collection
  - Maybe useful for national professionals from other sectors supporting surveillance of AMR in the context of the “One Health” approach
63 countries responded

<table>
<thead>
<tr>
<th>Region</th>
<th>Count</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>4</td>
<td>6.3%</td>
</tr>
<tr>
<td>Americas</td>
<td>19</td>
<td>30.2%</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>21</td>
<td>33.3%</td>
</tr>
<tr>
<td>Europe</td>
<td>10</td>
<td>15.9%</td>
</tr>
<tr>
<td>South-East Asia</td>
<td>3</td>
<td>4.8%</td>
</tr>
<tr>
<td>Western Pacific</td>
<td>6</td>
<td>9.5%</td>
</tr>
<tr>
<td>Low &amp; lower-middle income</td>
<td>18</td>
<td>28.6%</td>
</tr>
<tr>
<td>Upper-middle income</td>
<td>22</td>
<td>34.9%</td>
</tr>
<tr>
<td>High income</td>
<td>23</td>
<td>36.5%</td>
</tr>
<tr>
<td>GLASS countries</td>
<td>45</td>
<td>71.4%</td>
</tr>
<tr>
<td>Non-GLASS countries</td>
<td>18</td>
<td>28.6%</td>
</tr>
</tbody>
</table>
Q1: does the draft Manual provide sufficient guidance on the methods and metrics?

- Yes: 92%
- No: 6%
- Don't know: 2%

Q2: is the GLASS-AMR methodology presented in a clear manner?

- Yes: 90%
- No: 8%
- Don't know: 2%
Q3: does the draft Manual provide useful tools for putting the GLASS-AMR approach into practice?

Yes: 92%
No: 5%
Don’t know: 3%

Q5: Do you find the draft GLASS-AMR Manual 2.0 useful for assisting with enhancing your national AMR surveillance system?

Yes: 86%
No: 5%
Don’t know: 9%
Q4: is the inclusion of new specimen types, pathogens, and antimicrobials appropriate?

Yes
- Quite a number of countries proposed additional specimens, pathogens and pathogen-drug combinations.
- One country noted that the list may be challenging for some countries which are just starting or have insufficient resources.

No
- Concerns about the challenges the extended list is posing to countries.
- One country proposed to focus on standardization and harmonization of surveillance of resistance in bloodstream infections (and possibly UTIs) instead of adding new specimen types.

Don't know 11%
Q6: ... would your country be capable of starting anonymised individual data submission in the next stage of the GLASS implementation?

- **Yes**: 51%
- **No**: 20%
- **Don’t know**: 29%

All responding countries (N=63)

**Yes**
- Several countries are already submitting individual level data to international networks and more countries collect individual AMR data at the national level
- Will require additional efforts, improving national coordination, developing approaches for evaluation of surveillance sites, adjusting IT tools

**No**
- Limitations of the laboratory-centred systems, lack of human and IT resources.
- Several countries were not convinced by the provided rationale

**Don’t know**
- Further discussions/consultations with national authorities/stakeholders are required
Q7: ... In order to motivate continuous development of national AMR surveillance systems, GLASS would like to categorise the AMR data regarding quality and representativeness. Please indicate the elements you consider key for this categorization

- Quality assured microbiological data: 88.9%
- Geographical representation of patients: 71.4%
- Completeness of reported surveillance data: 66.7%
- Healthcare facility type of care representation: 66.7%
- National population sample representation: 65.1%
- Quality of epidemiological data (bias): 63.5%
- Community level representation: 47.6%
- Medical speciality representation: 42.9%
- Level of testing activity: 34.9%
Q8: Please share any additional comments you have on the draft GLASS-AMR Manual 2.0

- 25 countries used this open question to provide positive and useful comments, questions and suggested edits
- Several countries provided comprehensive reviews of the document
- As some countries are still sending their feedback, a more detailed overview of the feedback will be included in the final report that will be distributed after the consultation meeting in April 2021